New ETF Book by Larry Connors - Click here to read more
Barbara Burzynski, M.D., Robert Weaver, M.D., Eva Kubove, M.D., and Stanislaw R. Burzynski, M.D., Ph.D., will represent BRI and BC, presenting two reports of early results of combination gene-targeted agents in a specific group of patients treated at BC.
Pancreatic cancer continues to create very difficult therapeutic problems for clinicians. Standard chemotherapy has shown to be limited in managing the disease for the longer-term. The report being presented summarizes the initial effects of combination gene-targeted therapies to treat eleven patients with advanced pancreatic cancer, including a case study on a patient in complete response seven months after the diagnosis of his disease.
Hepatocellular carcinoma is a primary liver cancer that carries nearly 100% mortality and has shown to be highly resistant to conventional therapies. The discussion undertaken at the Congress looks at preliminary findings across a group of seven patients undergoing personalized treatment of their disease. Case reports highlighted involve two patients diagnosed with hepatocellular carcinoma who failed standard therapy; one of them relapsing post liver transplant. Both patients have achieved complete response.
"These cases require longer follow-up and confirmation in a larger patient population. However, the early results are quite compelling when you consider the deadly outcome of these advanced liver and pancreatic cancers," said Stanislaw R. Burzynski, M.D., Ph.D.
Burzynski Research Institute, Inc. (OTCBB: BZYR | Quote | Chart | News | PowerRating) is a biopharmaceutical company committed to developing treatment for cancer based on genomic and epigenomic principles. Research and development efforts are focused on basic research and Phase III clinical trials.
Forward-looking statements in this release are made pursuant to the safe harbor provisions of the federal securities laws. Burzynski Research Institute, Inc. cautions investors not to place undue reliance on the forward-looking statements contained in this press release. Information contained in forward-looking statements is based on current expectations and is subject to change, and future events may differ materially from those discussed herein due to a number of factors including, but not limited to, risks and uncertainties related to BRI's ability to obtain regulatory approval for antineoplastons A10 and AS2-1, risks associated with BRI's ability to raise sufficient capital from the development of its technology towards commercialization, and other risks described in BRI's periodic reports filed with the Securities and Exchange Commission. BRI does not undertake to update any such forward- looking statements or to publicly announce developments or events relating to the matters described herein.
SOURCE: Burzynski Research Institute, Inc.
For Burzynski Research Institute, Inc. Darlene Hodge, 713-335-5636 Darlene@burzynskiclinic.com or Carolyn Powers, 713-335-5664 Carolyn@burzynskiclinic.com or Amanda Cheslock, 212-446-1884 acheslock@sloanepr.com
More News:
Market Updates |
Stock Alerts |
All Trading News |
Stock Index
About TradingMarkets | Contact | Advertise | Careers | Link to Us | Site Map | Help | Terms & Conditions | Privacy Policy | Return Policy | Testimonials | Feedback
The Connors Group, Inc. ("Company") is not an investment advisory service, nor a registered investment advisor or broker-dealer and does not purport to tell or suggest which securities or currencies customers should buy or sell for themselves. The analysts and employees or affiliates of Company may hold positions in the stocks, currencies or industries discussed here. You understand and acknowledge that there is a very high degree of risk involved in trading securities and/or currencies. The Company, the authors, the publisher, and all affiliates of Company assume no responsibility or liability for your trading and investment results. Factual statements on the Company's website, or in its publications, are made as of the date stated and are subject to change without notice.
It should not be assumed that the methods, techniques, or indicators presented in these products will be profitable or that they will not result in losses. Past results of any individual trader or trading system published by Company are not indicative of future returns by that trader or system, and are not indicative of future returns which be realized by you. In addition, the indicators, strategies, columns, articles and all other features of Company's products (collectively, the "Information") are provided for informational and educational purposes only and should not be construed as investment advice. Examples presented on Company's website are for educational purposes only. Such set-ups are not solicitations of any order to buy or sell. Accordingly, you should not rely solely on the Information in making any investment. Rather, you should use the Information only as a starting point for doing additional independent research in order to allow you to form your own opinion regarding investments. You should always check with your licensed financial advisor and tax advisor to determine the suitability of any investment.
HYPOTHETICAL OR SIMULATED PERFORMANCE RESULTS HAVE CERTAIN INHERENT LIMITATIONS. UNLIKE AN ACTUAL PERFORMANCE RECORD, SIMULATED RESULTS DO NOT REPRESENT ACTUAL TRADING AND MAY NOT BE IMPACTED BY BROKERAGE AND OTHER SLIPPAGE FEES. ALSO, SINCE THE TRADES HAVE NOT ACTUALLY BEEN EXECUTED, THE RESULTS MAY HAVE UNDER- OR OVER-COMPENSATED FOR THE IMPACT, IF ANY, OF CERTAIN MARKET FACTORS, SUCH AS LACK OF LIQUIDITY. SIMULATED TRADING PROGRAMS IN GENERAL ARE ALSO SUBJECT TO THE FACT THAT THEY ARE DESIGNED WITH THE BENEFIT OF HINDSIGHT. NO REPRESENTATION IS BEING MADE THAT ANY ACCOUNT WILL OR IS LIKELY TO ACHIEVE PROFITS OR LOSSES SIMILAR TO THOSE SHOWN.
The Connors Group, Inc.
10 Exchange Place, Suite 1800
Jersey City, NJ 07302
© Copyright 2009 The Connors Group, Inc.
